Cold Chain Warehouse

A Cold Chain Warehouse is a facility, together with its operating activities, for maintaining the conditions assigned to temperature-sensitive products and preserving traceable evidence through receipt, storage, staging and handover. The useful definition includes both the physical environment and the people, instructions and records connecting that environment to identifiable stock.

It is not simply a refrigerator, a universal temperature range or a statement that every room and process has been validated. Nor does the name establish transport qualification or authorise supply after a suspected temperature excursion. Those are separate questions requiring evidence appropriate to the product, activity and decision.

The regulatory examples here concern the European Commission’s 2013/C 343/01 GDP guidelines for wholesale distribution of human medicines. The introduction describes wholesale distribution as activities including procuring, holding, supplying and exporting, apart from supply to the public. These guidelines are not a common rulebook for food, veterinary medicines or all temperature-sensitive goods. Those activities, and operations in other jurisdictions including the United States, need separate assessment.

Start with the applicable product storage instructions, not the room’s informal name. In the proposed operating model, record the instruction source and version, the products it covers, relevant handling precautions and the person responsible for resolving ambiguity. Do not invent an allowable time outside those conditions or treat a room setpoint as the product instruction.

For human-medicines wholesale distribution, Commission GDP section 5.1 says operations should preserve product identity and follow information on the outer packaging. Section 5.4 says products needing special storage or security measures should be prioritised and, following appropriate checks, immediately transferred to appropriate storage. Section 3.2 addresses weather protection at receiving and dispatch bays and control of inbound and outbound goods.

This fictional record structure follows actual custody and location history. If a transfer time is uncertain, preserve that uncertainty rather than assigning a convenient timestamp. Keep product identity, quantity, location and quality status connected without treating them as interchangeable facts.

Mapping, monitoring, calibration, maintenance and qualification answer different questions. Use these working distinctions when assembling the evidence file; one activity does not replace the others.

Commission GDP section 3.2.1 says an initial temperature mapping exercise should take place before use under representative conditions. Monitoring devices should be located using its results, including areas experiencing extremes of fluctuation. Mapping should be repeated according to risk assessment or significant modifications to the facility or temperature-controlling equipment—not an invented annual room-mapping rule. The section also provides a risk-assessment approach for small room-temperature premises of a few square metres.

Section 3.3 calls for planned maintenance of key equipment, calibration intervals based on risk and reliability, calibration traceable to a national or international measurement standard, appropriately set alarms and regular alarm testing. Section 3.3.2 addresses risk-based identification of necessary qualification or validation and its performance before use and after significant changes.

In this evidence model, describe what was observed before interpreting it. An air sensor observation is recorded as air temperature at the sensor’s position. A product observation needs its own description: what was measured, where, how and when. Do not relabel an air reading as a direct measurement of every case or assume that a later product measurement reconstructs an earlier interval.

For each evidence source, retain its identifier, position, time basis, coverage interval and relevant calibration or equipment information. Ask whether the observation represents the stock location and circumstances being assessed. A useful assessment distinguishes available observations, justified interpretation and unresolved uncertainty.

The stock-history intersection is especially important after a move. Looking only at what remains in a room can omit cases that shared the uncertain interval and then left. Looking only at a batch identifier can unnecessarily merge groups with different, independently supported histories.

Treat a monitoring gap as missing evidence, not automatically as a measured temperature excursion. Its duration describes the unknown interval. Neither an apparently functioning refrigeration unit nor a normal reading after recovery fills that interval by itself. Conversely, the missing record alone does not establish that every case experienced an unacceptable temperature.

Commission GDP section 3.3.1 says procedures should be defined for computerised-system failure or breakdown, including data restoration. The following is a fictional contingency sequence, not a prescribed GDP form or automatic release pathway.

1. Protect the stock. Identify candidate affected groups, pause their supply and maintain product-assigned conditions while the event is assessed.
2. Establish the evidence problem. Distinguish missing transmission, unavailable records, instrument failure and an observed condition deviation; preserve the original findings.
3. Use the agreed contingency. Arrange suitable alternative monitoring or storage, checking destination suitability, capacity and evidence coverage rather than merely moving cases to a colder place.
4. Record movements contemporaneously where possible. Capture case identities, quantities, actual times, origin, destination, operator and the instruction authorising the movement. Mark uncertain or retrospectively established details.
5. Recover and reconcile. Preserve recovered data and original manual records, identify duplicate entries, compare timestamps and quantities, and document discrepancies without silently replacing the originals.
6. Refer disposition to an authorised, competent person. Supply the stock-history boundary, representative evidence, unresolved uncertainty and relevant product information.

For the fictional manual fallback, assign each record a reference and link any later transcription to it. Distinguish the event time from the transcription time, record who reconciled the entries and explain corrections. A manual movement entry establishes the reported movement; it is not a temperature measurement. This model does not make paper inherently unacceptable or require a scan or electronic signature for every action.

CC-82 is fictional record practice involving 60 cases. Before the event, 30 cases are in Room A and 30 are in Room B. Ten of Room A’s cases move to a staging bay at 09:20; 20 remain in Room A. At 09:40, record review identifies a Room A monitoring gap from 09:10 to 09:40. The move occurred before the gap was identified, but during the missing interval.

The gap is 30 minutes of unknown conditions in the Room A monitoring record, not 30 minutes of measured product exposure. The 09:20 movement entry establishes a reported location change, not a temperature. The initial affected candidate set therefore contains 30 cases: the 20 remaining in Room A plus the 10 moved cases with linked Room A history.

An authorised reviewer keeps the 30 candidate cases on conservative hold pending representative measurements or other relevant evidence and product-specific assessment. Measurements obtained now can help establish current conditions, but their relevance to the missing interval needs assessment; they do not automatically resolve it. Any protective relocation is recorded without changing the hold merely because the destination is suitable.

Room B is outside this particular affected candidate set because of its separately reviewed evidence, not because its cases have a different location label or no alarm. That conclusion is limited to this event. It is not a declaration that Room B’s cases are approved for every other quality or supply purpose.

In the proposed operating model, a hold prevents the relevant supply decision while assessment continues. It does not suspend the product’s storage instructions. Keep held goods under their assigned conditions, with clear identity, restricted handling and instructions covering any necessary protective movement.

Commission GDP section 3.2 allows physical segregation or an equivalent electronic system for products pending disposition or removed from saleable stock, including suspected falsification and returns. A system replacing physical segregation should provide equivalent security and be validated. This is not blanket permission: the section says falsified, expired, recalled and rejected products should be immediately physically segregated in a dedicated area away from other medicinal products. Third-country medicines not intended for the Union market should also be physically segregated.

Commission GDP section 5.5 says stock should rotate by first expiry, first out (FEFO), with documented exceptions. In this operating model, apply rotation only within stock eligible for the intended action; an earlier expiry or customer reservation never bypasses a hold.

The human instruction identifies the cases, decision, evidence considered, unresolved issues, required conditions and decision-maker. A movement instruction is not a disposition instruction. An alarm acknowledgement, restored sensor or completed maintenance task is not, by itself, permission to supply.

Returns add an external history. Commission GDP section 6.3 calls for a written, risk-based process considering the product, specific storage requirements and time since original dispatch, with returns conducted under national law and contractual arrangements. Products that have left the distributor’s premises should return to saleable stock only when all its listed conditions are confirmed:

• Unopened, undamaged secondary packaging; good condition; no expiry or recall.
• An acceptable return time for customers without a wholesale distribution authorisation or pharmacies authorised to supply the public. The guideline gives 10 days as an example, not a universal deadline or acceptance rule.
• Customer demonstration of transport, storage and handling in compliance with the product’s specific requirements.
• Examination and assessment by a sufficiently trained, competent person authorised to do so.
• Reasonable evidence that the distributor supplied that customer; a known batch number for products bearing safety features; and no reason to believe the product has been falsified.

For medicines requiring specific temperature storage conditions, section 6.3 additionally requires documented evidence of authorised storage conditions throughout the entire time before return to saleable stock. Its evidence chain covers delivery to the customer, examination, opening the transport packaging, returning the product to that packaging, collection and return to the distributor, and return to the distribution-site refrigerator.

Where a deviation occurred, the guideline calls for a risk assessment on which product integrity can be demonstrated. Read with its product-specific return process, this is not automatic acceptance because the goods look intact, arrive within the example period or are cold on arrival. Unresolved evidence remains a decision problem.

Section 6.3 says returned goods restored to saleable stock should be positioned for effective FEFO. It also states that recovered stolen products cannot return to saleable stock and be sold to customers. In the fictional record model, receipt of a return and approval for resale remain separate recorded events.

For EU human-medicines wholesale distribution, Commission GDP section 2.2 lists deciding on the final disposition of returned, rejected, recalled or falsified products, and approving returns to saleable stock, among the responsible person’s responsibilities. The responsible person may delegate duties but not responsibilities; their written job description should define their decision-making authority.

Outsourcing changes who performs an activity; the evidence boundary still needs definition. Commission GDP Chapter 7 calls for outsourced activities to be defined, agreed and controlled, with a written contract establishing each party’s duties. The contract giver remains responsible for contracted-out activities and for assessing the acceptor’s competence and ensuring GDP through the contract and audits. It should provide the information needed for product-specific operations.

Commission GDP section 9.2 says manufacturer- or packaging-defined conditions should be maintained during transport. Third-party transport contracts should encompass Chapter 7, and providers should receive relevant consignment conditions. Transport deviations such as temperature excursions or product damage should be reported to the distributor and recipient of the affected medicines. Section 9.2 also says a procedure should be in place for investigating and handling temperature excursions.

Section 9.4 calls for qualified equipment for transporting temperature-sensitive products. A warehouse evidence file is not a substitute for that transport evidence, and transport qualification does not decide the disposition of a warehouse case group with an unresolved history.

• In the fictional handover record, identify the cases, physical transfer time, receiving party and applicable instructions.
• Identify which party monitors each staging, loading and transport interval, and where the resulting evidence can be obtained.
• Carry forward holds, unresolved gaps and escalation contacts. Do not interpret a delivery acknowledgement as quality approval.
• Record rejected or delayed handovers and the conditions under which stock remains while a human resolves the next action.

For a useful review, assemble the applicable product instructions, location history, relevant mapping and equipment records, monitoring evidence, manual contingency records and scoped human decisions. Assess the connection between those records rather than counting documents or relying on a dashboard average.

• Can each case group be linked to the conditions and evidence relevant to its actual history?
• Are missing observations distinguished from measured deviations and from later interpretations?
• Does the affected-set search include stock that moved before discovery?
• Do held goods remain under suitable conditions without accidental supply eligibility?
• Are manual and recovered records reconciled without manufacturing missing measurements?
• Does the handover identify outstanding restrictions and the next responsible decision-maker?

These are original review prompts, not universal KPI targets or inspection sample counts. The practical outcome is a defensible instruction about identified stock, with the evidence and uncertainty visible to the authorised human making the decision.